Clover Begins Patient Dosing In Phase 3 Trial Of Scb 2019 As Heterologous Covid-19 Booster Following Prior Vaccination With Inactivated Mrna Or Viral Vector Vaccines

Clover Biopharmaceuticals, Ltd., A Global Clinical-Stage Biotechnology Company, Announced The First Participants Have Been Dosed In A Phase 3 Study Evaluating The Safety And Immunogenicity Of Clover